Journal article
Targeted Therapies for Prostate Cancer
Cancer investigation, Vol.33(7), pp.276-285
08/09/2015
DOI: 10.3109/07357907.2015.1033105
PMID: 25951372
Abstract
New therapies for prostate cancer have emerged over the past three years. Nevertheless, none of these agents is curative, and unfortunately, patients often ultimately develop resistance to these agents. Therefore, the development of innovative and effective therapies that overcome these resistances is necessary. Unfortunately, the results of a phase III trial evaluating docetaxel in combination with targeted therapies demonstrated no difference in survival. Moreover, scarce data on the combination of a targeted therapy with new agents are currently available. New trials are investigating these possible combination treatments; the results of these (on-going) clinical studies are awaited.
Details
- Title: Subtitle
- Targeted Therapies for Prostate Cancer
- Creators
- Roberto Petrioli - University of SienaEdoardo Francini - Policlinico Umberto IAnna Ida Fiaschi - University of SienaLetizia Laera - University of SienaGiandomenico Roviello - University of Siena
- Resource Type
- Journal article
- Publication Details
- Cancer investigation, Vol.33(7), pp.276-285
- DOI
- 10.3109/07357907.2015.1033105
- PMID
- 25951372
- NLM abbreviation
- Cancer Invest
- ISSN
- 0735-7907
- eISSN
- 1532-4192
- Publisher
- Informa Healthcare
- Number of pages
- 10
- Language
- English
- Date published
- 08/09/2015
- Academic Unit
- Internal Medicine
- Record Identifier
- 9985221246002771
Metrics
1 Record Views